A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia

NCT02251548 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

85

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Leukemia

Interventions

DRUG: Ibrutinib
DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: Rituximab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]